Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00338-0722-01 00338-0722 PEMETREXED PEMETREXED 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog INTRAVENTRICULAR Aug. 18, 2022 In Use
00143-9136-01 00143-9136 Mitomycin Mitomycin 40.0 mg/1 Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Oct. 1, 2022 In Use
16729-0548-63 16729-0548 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Aug. 18, 2022 In Use
16729-0545-63 16729-0545 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Aug. 18, 2022 In Use
16714-0679-01 16714-0679 Sunitinib malate Sunitinib malate 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Feb. 18, 2022 In Use
16714-0678-01 16714-0678 Sunitinib malate Sunitinib malate 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Feb. 18, 2022 In Use
16714-0677-01 16714-0677 Sunitinib malate Sunitinib malate 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Feb. 18, 2022 In Use
16714-0676-01 16714-0676 Sunitinib malate Sunitinib malate 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Feb. 18, 2022 In Use
55150-0326-01 55150-0326 CLOFARABINE CLOFARABINE 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Oct. 3, 2022 In Use
55513-0488-02 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
55513-0488-24 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
55513-0488-96 55513-0488 Sotorasib LUMAKRAS 120.0 mg/1 Chemotherapy RAS Inhibitor KRAS G12C Oral May 28, 2021 In Use
55150-0431-01 55150-0431 DACTINOMYCIN DACTINOMYCIN 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous March 15, 2021 In Use
55150-0928-02 55150-0928 DACTINOMYCIN DACTINOMYCIN 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous March 15, 2021 In Use
63323-0104-05 63323-0104 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous July 18, 2001 In Use
63323-0104-25 63323-0104 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous July 18, 2001 In Use
63323-0104-50 63323-0104 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous July 18, 2001 In Use
57962-0007-12 57962-0007 Ibrutinib Imbruvica 70.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Aug. 24, 2022 In Use
63323-0104-06 63323-0104 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Sept. 9, 2022 In Use
58468-7860-03 58468-7860 Vandetanib CAPRELSA 300.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Oral June 24, 2022 In Use
68001-0541-36 68001-0541 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 31, 2022 In Use
68001-0543-41 68001-0543 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 1, 2022 In Use
68001-0544-41 68001-0544 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 1, 2022 In Use
70121-1233-01 70121-1233 Pemetrexed Pemetrexed disodium 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Aug. 10, 2022 In Use
70511-0161-05 70511-0161 Bortezomib Bortezomib 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug. 11, 2022 In Use
70511-0162-02 70511-0162 Bortezomib Bortezomib 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug. 11, 2022 In Use
70518-3263-00 70518-3263 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Nov. 2, 2021 In Use
70518-3263-01 70518-3263 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Feb. 15, 2022 In Use
70518-3263-03 70518-3263 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Sept. 11, 2022 In Use
70518-3263-04 70518-3263 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Oct. 19, 2022 In Use
71288-0118-10 71288-0118 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 26, 2022 In Use
71288-0137-20 71288-0137 MITOMYCIN MITOMYCIN 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Sept. 8, 2022 In Use
71288-0138-50 71288-0138 MITOMYCIN MITOMYCIN 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Sept. 8, 2022 In Use
71288-0139-51 71288-0139 MITOMYCIN MITOMYCIN 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Sept. 6, 2022 In Use
72205-0183-01 72205-0183 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 27, 2022 In Use
72266-0243-01 72266-0243 Bortezomib Bortezomib 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug. 23, 2022 In Use
72266-0244-01 72266-0244 Bortezomib Bortezomib 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug. 23, 2022 In Use
72819-0185-09 72819-0185 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2022 In Use
72819-0186-03 72819-0186 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2022 In Use
67457-0254-30 67457-0254 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 23, 2016 In Use
68152-0108-09 68152-0108 Belinostat Beleodaq 500.0 mg/10mL Chemotherapy Enzyme Inhibitor HDAC Intravenous July 21, 2014 Nov. 30, 2022 In Use
68001-0549-41 68001-0549 Pemetrexed Pemetrexed 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 27, 2022 June 28, 2022 No Longer Used
73150-0200-12 73150-0200 umbralisib UKONIQ 260.2 mg/1 Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Oral Feb. 5, 2021 July 31, 2023 No Longer Used
00054-0248-12 00054-0248 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0248-22 00054-0248 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0249-12 00054-0249 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0249-13 00054-0249 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00054-0249-22 00054-0249 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 28, 2018 In Use
00024-5824-11 00024-5824 Cabazitaxel Jevtana Chemotherapy Antimitotic Agent Taxane Intravenous June 17, 2010 In Use
00069-0251-60 00069-0251 CRIZOTINIB Xalkori 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov. 20, 2023 In Use
00069-0507-60 00069-0507 CRIZOTINIB Xalkori 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov. 20, 2023 In Use
00069-1500-60 00069-1500 CRIZOTINIB Xalkori 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK, HGFR, ROS1, RON Oral Nov. 20, 2023 In Use
00703-4156-11 00703-4156 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 1, 2002 Jan. 31, 2024 No Longer Used
00703-4156-91 00703-4156 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 1, 2002 Jan. 31, 2013 No Longer Used
00703-5656-01 00703-5656 Etoposide Toposar 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Aug. 1, 1996 Jan. 31, 2024 No Longer Used
00703-5656-91 00703-5656 Etoposide Toposar 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous May 16, 2013 June 30, 2017 No Longer Used
00143-9204-01 00143-9204 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 14, 2021 In Use
00143-9205-01 00143-9205 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 14, 2021 In Use
00143-9385-01 00143-9385 Decitabine Decitabine 50.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous April 15, 2022 In Use
00955-1020-01 00955-1020 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 21, 2010 In Use
00955-1021-04 00955-1021 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 21, 2010 In Use
00955-1022-08 00955-1022 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 23, 2016 In Use
44087-4000-00 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-04 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-05 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-06 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-07 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-08 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-09 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
48818-0001-01 48818-0001 Pralatrexate Folotyn 20.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 24, 2009 June 30, 2023 No Longer Used
48818-0001-02 48818-0001 Pralatrexate Folotyn 20.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 24, 2009 Feb. 29, 2024 No Longer Used
43598-0865-60 43598-0865 Bortexomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Nov. 1, 2019 In Use
50268-0761-11 50268-0761 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 23, 2017 In Use
50268-0761-12 50268-0761 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 23, 2017 In Use
50268-0762-11 50268-0762 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 23, 2017 In Use
50268-0762-12 50268-0762 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 23, 2017 In Use
50268-0527-15 50268-0527 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 26, 2021 In Use
50419-0208-01 50419-0208 Radium Ra 223 dichloride Xofigo 30.0 uCi/mL Chemotherapy Radiopharmaceutical Radium 223 Intravenous May 20, 2013 In Use
50419-0385-01 50419-0385 Copanlisib Aliqopa 15.0 mg/mL Chemotherapy Enzyme Inhibitor PI3K Intravenous Sept. 14, 2017 In Use
50419-0385-72 50419-0385 Copanlisib Aliqopa 15.0 mg/mL Chemotherapy Enzyme Inhibitor PI3K Intravenous Oct. 30, 2018 In Use
51144-0002-12 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
51144-0002-60 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
50419-0392-01 50419-0392 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK OROPHARYNGEAL July 26, 2019 In Use
51144-0001-60 51144-0001 Tucatinib TUKYSA 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
51991-0797-98 51991-0797 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Subcutaneous Aug. 7, 2017 Jan. 31, 2024 No Longer Used
54879-0027-11 54879-0027 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous May 29, 2019 In Use
55390-0370-10 55390-0370 Topotecan Hydrochloride Topotecan Hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 1, 2020 In Use
59923-0702-02 59923-0702 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 20, 2008 In Use
59923-0702-05 59923-0702 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 20, 2008 In Use
59923-0714-02 59923-0714 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous March 1, 2019 In Use
59923-0715-05 59923-0715 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous March 1, 2019 In Use
59923-0716-15 59923-0716 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 6, 2019 In Use
59923-0721-60 59923-0721 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 1, 2020 In Use
59923-0722-12 59923-0722 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 1, 2020 In Use
61703-0342-09 61703-0342 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 1, 2004 In Use
61703-0342-22 61703-0342 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 1, 2004 In Use
61703-0342-50 61703-0342 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 1, 2004 In Use
64679-0793-01 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-02 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-03 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use

Found 10,000 results in 9 milliseconds — Export these results